Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Building a balanced search formula for pharmacovigilance and literature monitoring

Posted on March 21st, 2017 by in Pharmacovigilance

Adverse drug reactions are an important risk for patient safety and have significant impact on the costs of health systems. A rise in number of diseases has consequently led to a rise in number of drug consumption, which has also brought about an increase in the number of adverse drug events and drug toxicity cases. Continue reading “Building a balanced search formula for pharmacovigilance and literature monitoring” »

Working to Uncover the Mode of Action

Posted on March 2nd, 2017 by in Pharma R&D

The New Year has brought some new talent into the Myelo Therapeutics team. In January we welcomed Susann, our new postdoctoral researcher. We’re excited to have someone with her experience, which includes studying molecular biology in Dresden and Heidelberg, Continue reading “Working to Uncover the Mode of Action” »

Giving Pharma & Biotech Start-Ups a Leg Up

Posted on February 10th, 2017 by in Pharma R&D

Many of the greatest innovations in the pharma world today are emerging from start-up biotech firms. Acknowledging and empowering these small-but-mighty companies was the simple idea behind The Hive, Continue reading “Giving Pharma & Biotech Start-Ups a Leg Up” »

An Update from Myelo: Expanding Our Team and Evaluating Data

Posted on December 14th, 2016 by in Pharma R&D

The focus of our current non-clinical research at Myelo Therapeutics is to fully elucidate the mode of action for prevention of myelosuppression as well as Myelo001’s antiviral capabilities. But to achieve this goal, it’s important to have highly skilled and motivated personnel within your team. Continue reading “An Update from Myelo: Expanding Our Team and Evaluating Data” »

  1. 1
  2. 2